As of November 8, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Veradermics, Inc. The largest reported stake is Longitude Capital Partners V, LLC's, at 11.3%. 13 filings are on record since February 11, 2026 (Schedule 13D/A, May 5, 2026).
Sell to companies like Veradermics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Jpmorgan Chase & Co. · Sole voting: 2,231,159 · Shared voting: 1 · Sole dispositive: 2,374,185 · Shared dispositive: 1 · SCHEDULE 13G, 2026-10-13
- · Reporting person: Montanova Capital, LLC · Sole voting: 0 · Shared voting: 3,718,970 · Sole dispositive: 0 · Shared dispositive: 3,718,970 · SCHEDULE 13D/A, 2026-08-21
- · Reporting person: SR One Capital Management, LLC · Sole voting: 0 · Shared voting: 2,080,119 · Sole dispositive: 0 · Shared dispositive: 2,080,119 · SCHEDULE 13D/A, 2026-08-14
- · Reporting person: Fmr LLC · Sole voting: 3,193,077 · Shared voting: 0 · Sole dispositive: 3,193,181 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-06
- · Holder: Viking Global Investors LP · Percent: 4.5% · SCHEDULE 13G/A
Veradermics, Inc has 13 Schedule 13D or 13G filings on record since 2026-02-11. 4 holders' latest filing reports 5% or more of common stock, par value $0.00001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Longitude Capital Partners V, LLC | 11.3% | 2,600,399 | SCHEDULE 13D/A, 2026-05-05 | 2026-05-01 |
| Montanova Capital, LLC | 8.8% | 3,718,970 | SCHEDULE 13D/A, 2026-08-21 | 2026-08-19 |
| Fmr LLC | 7.6% | 3,193,181 | SCHEDULE 13G, 2026-08-06 | 2026-06-30 |
| Jpmorgan Chase & Co. | 5.6% | 2,374,502 | SCHEDULE 13G, 2026-10-13 | 2026-09-30 |
| SR One Capital Management, LLC | 4.9% | 2,080,119 | SCHEDULE 13D/A, 2026-08-14 | 2026-08-12 |
| Viking Global Investors LP | 4.5% | 1,690,555 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Citadel Advisors LLC | 4.5% | 1,870,775 | SCHEDULE 13G, 2026-05-07 | 2026-04-30 |
| Seven Fleet Capital Management LP | 0.2% | 80,000 | SCHEDULE 13D, 2026-05-05 | 2026-05-01 |
Holding shares or following this stake? See who's behind Veradermics, Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Veradermics, Inc and the records around it.
Veradermics, Inc elsewhere on the record
- Company profile and every filing May 2026
- Form D filing May 2026
- Form D filing Oct 2025
- Who owns it
Companies that share a holder
- Longitude Capital Partners V, LLC also filed stake reports on 3 other companies: Entera Bio Ltd. (Aug 2026), CytomX Therapeutics, Inc. (May 2026), Mobia Medical, Inc. (May 2026)
- Seven Fleet Master Fund LP also filed stake reports on 3 other companies: Entera Bio, Ltd. (the "Issuer") (Aug 2026), CytomX Therapeutics, Inc. (May 2026), CG Oncology, Inc. (Oct 2025)
- SR One Capital Management, LLC also filed stake reports on 6 other companies: ADARx Pharmaceuticals, Inc. (Oct 2026), Zenas BioPharma, Inc. (Aug 2026), Odyssey Therapeutics, Inc. (May 2026)
Watch Veradermics, Inc
Get an email when Veradermics, Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Veradermics, Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Veradermics, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Veradermics, Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
22 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Montanova Capital, LLC | 0 | 3,718,970 | 0 | 3,718,970 | SCHEDULE 13D/A, 2026-08-21 |
| Averill Master Fund, Ltd. | 0 | 3,106,937 | 0 | 3,106,937 | SCHEDULE 13D/A, 2026-08-21 |
| Averill Madison Master Fund, Ltd. | 0 | 612,033 | 0 | 612,033 | SCHEDULE 13D/A, 2026-08-21 |
| Aaron Cowen | 0 | 3,718,970 | 0 | 3,718,970 | SCHEDULE 13D/A, 2026-08-21 |
| Fmr LLC | 3,193,077 | 0 | 3,193,181 | 0 | SCHEDULE 13G, 2026-08-06 |
| Abigail P. Johnson | 0 | 0 | 3,193,181 | 0 | SCHEDULE 13G, 2026-08-06 |
| Jpmorgan Chase & Co. | 2,231,159 | 1 | 2,374,185 | 1 | SCHEDULE 13G, 2026-10-13 |
| SR One Capital Management, LLC | 0 | 2,080,119 | 0 | 2,080,119 | SCHEDULE 13D/A, 2026-08-14 |
| SR One Capital Fund II Aggregator, LP | 0 | 1,403,959 | 0 | 1,403,959 | SCHEDULE 13D/A, 2026-08-14 |
| SR One Capital Partners II, LP | 0 | 1,403,959 | 0 | 1,403,959 | SCHEDULE 13D/A, 2026-08-14 |
| Amzl, LP | 0 | 676,160 | 0 | 676,160 | SCHEDULE 13D/A, 2026-08-14 |
| SR One Capital SMA Partners, LP | 0 | 676,160 | 0 | 676,160 | SCHEDULE 13D/A, 2026-08-14 |
| Simeon George | 0 | 2,080,119 | 0 | 2,080,119 | SCHEDULE 13D/A, 2026-08-14 |
The latest filing identifies Veradermics, Inc by CUSIP 922967104 and gives its principal executive office as 470 James St., New Haven, CT 06513 (SCHEDULE 13G, 2026-10-13).
Source of funds (Item 3)
The information contained in Item 3 of the Original Schedule 13D is hereby amended and supplemented by adding the text set forth below after the last paragraph: Open Market Sales On August 19, 2026, (i) Averill Master Fund sold 690,601 shares of Common Stock in the open market at a per share price of $107.25, and (ii) Averill Madison Master Fund sold 59,399 shares of Common Stock in the open market, at a per share price of $107.25.Montanova Capital, LLC, SCHEDULE 13D/A, 2026-08-21
Not applicable.SR One Capital Management, LLC, SCHEDULE 13D/A, 2026-08-14
Purpose of Transaction (Item 4)
SR One Capital Management, LLC
On August 12, 2026, SR One Fund II Aggregator and AMZL sold an aggregate of 321,749 shares of the Common Stock of the Issuer in a privately negotiated transaction (the "Sale"). In the Sale, SR One Fund II Aggregator sold 217,162 shares of Common Stock and AMZL sold 104,587 shares of Common Stock, in each case at a price of $104.30 per share, for aggregate consideration of approximately $33,558,420. Following the Sale, SR One Fund II Aggregator now holds 1,403,959 shares of Common Stock (the "SR One Fund II Aggregator Shares"), and AMZL now holds 676,160 shares of Common Stock (the "AMZL Shares"). Collectively, the Funds now hold a total of 2,080,119 shares of Common Stock of the Issuer (the "Fund Shares"). Depending on market conditions and other factors, the Funds may dispose of additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-08-14; the filing has the rest
Longitude Capital Partners V, LLC
The information set forth in Item 4 of the Original Schedule 13D is incorporated herein by reference.Item 4 of the SCHEDULE 13D/A filed 2026-05-05
Seven Fleet Capital Management LP
The Reporting Persons purchased the Shares based on the Reporting Persons' belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in Item 4(a) through (j) of this Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in communications …The first part of Item 4 of the SCHEDULE 13D filed 2026-05-05; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-11 | Suvretta Capital Management, LLC | 11.9% | SCHEDULE 13D |
| 2026-02-11 | SR One Capital Management, LLC | 6.4% | SCHEDULE 13D |
| 2026-02-12 | Viking Global Investors LP | 5.8% | SCHEDULE 13G |
| 2026-02-12 | Longitude Capital Partners V, LLC | 12.5% | SCHEDULE 13D |
| 2026-05-05 | Suvretta Capital Management, LLC | 9.9% | SCHEDULE 13D/A |
| 2026-05-05 | Seven Fleet Capital Management LP | 0.2% | SCHEDULE 13D |
| 2026-05-05 | Longitude Capital Partners V, LLC | 11.3% | SCHEDULE 13D/A |
| 2026-05-07 | Citadel Advisors LLC | 4.5% | SCHEDULE 13G |
| 2026-05-15 | Viking Global Investors LP | 4.5% | SCHEDULE 13G/A |
| 2026-08-06 | Fmr LLC | 7.6% | SCHEDULE 13G |
| 2026-08-14 | SR One Capital Management, LLC | 4.9% | SCHEDULE 13D/A |
| 2026-08-21 | Montanova Capital, LLC | 8.8% | SCHEDULE 13D/A |
| 2026-10-13 | Jpmorgan Chase & Co. | 5.6% | SCHEDULE 13G |
Questions about who owns Veradermics, Inc
Who owns Veradermics, Inc?
On this page, 4 holders' latest ownership filings report 5% or more of Veradermics, Inc: Longitude Capital Partners V, LLC (11.3%, Schedule 13D/A, filed 2026-05-05), Montanova Capital, LLC (8.8%, Schedule 13D/A, filed 2026-08-21), Fmr LLC (7.6%, Schedule 13G, filed 2026-08-06) and Jpmorgan Chase & Co. (5.6%, Schedule 13G, filed 2026-10-13).
Who are the largest shareholders of Veradermics, Inc?
By the share each holder's latest filing reports, the largest holders of Veradermics, Inc on this page are Longitude Capital Partners V, LLC (11.3%), Montanova Capital, LLC (8.8%) and Fmr LLC (7.6%).
When did Longitude Capital Partners V, LLC buy into Veradermics, Inc?
The filings give report dates, not purchase dates. The earliest filing from Longitude Capital Partners V, LLC on this page is the Schedule 13D, filed 2026-02-12, reporting 12.5%; its latest, Schedule 13D/A filed 2026-05-05, reports 11.3%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Veradermics, Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 7, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| May 15, 2026 | Form D, private offering | $30M sold | Form D page | Source |
| April 30, 2026 | IPO filing, Form 424B4 | — | IPO filings | Source |
| April 27, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| February 4, 2026 | IPO filing, Form 424B4 | $17 a share | IPO filings | Source |
| January 28, 2026 | IPO filing, Form S-1/A | $14 to $16 a share | IPO filings | Source |
| January 9, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| October 28, 2025 | Form D, private offering | $135M sold | Form D page | Source |
| December 10, 2024 | Form D, private offering | $66.57M sold | Form D page | Source |
Veradermics, Inc: every filing and event
Tools for this story
Each opens in a new tab, filled in for Veradermics, Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.